News
PRESS RELEASE
Five Sisters Join Sarasota Memorial Study Advancing Earlier Pancreatic Cancer Detection
Five sisters with a family history of pancreatic cancer were among the first to enroll in a Sarasota Memorial Hospital study evaluating LINFU®, Adenocyte’s novel approach to earlier pancreatic cancer detection. Their story underscores the urgent need for better screening options for high-risk families — and the hope that earlier detection can change the future of pancreatic cancer.
RELATED MEDIA
SMH Podcast: Advancing Earlier Detection for High-Risk Pancreatic Cancer Patients
Kenneth Meredith, MD, chief of gastrointestinal oncology at SMH’s Brian D. Jellison Cancer Institute and principal investigator of the local study, discusses LINFU® and its potential role in helping identify precancerous pancreatic changes in high-risk patients who have no signs or symptoms of the disease.
PRESS RELEASE
iGan Partners Invests in Adenocyte Ltd to Advance the Early Detection of Pancreatic Cancer
Adenocyte announced a major financing milestone, with iGan Partners leading the first close of a $10 million round to accelerate expansion of LINFU®, its patented platform for earlier pancreatic cancer detection in high-risk patients. The investment supports Adenocyte’s continued clinical adoption, commercial growth, and mission to bring a scalable early-detection model to pancreatic cancer.
RELATED MEDIA
Lee Health: A New Way to Catch Pancreatic Cancer Earlier
Mark Bloomston, MD, surgical oncologist at Lee Health, discusses LINFU® and how microbubble-enhanced ultrasound may help doctors collect pancreatic cellular material for analysis in patients at increased risk.